Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -2.24%70 10-Year ROIIC % is 16.29 as of Dec. 2025. GuruFocus rates NGM:MCLR with a GF Score™ of 70/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 695 Medical Devices & Instruments companies, Medclair AB ranks better than 73.81% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Medclair AB's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 16.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medclair AB's 10-Year ROIIC % or its related term are showing as below:
NGM:MCLR's 10-Year ROIIC % is ranked better than 73.81% of 695
companies
in the Medical Devices & Instruments industry
Industry Median: 2.31
vs NGM:MCLR: 16.29
Medclair AB (NGM:MCLR) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medclair AB 10-Year ROIIC % Related Terms
Medclair AB 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medclair AB's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: 10-Year ROIIC % Comparison
For the Medical Devices subindustry, Medclair AB's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medclair AB's 10-Year ROIIC % falls into.
Medclair AB's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 6.166 (Dec. 2025) - -1.725 (Apr. 2015) )
/
( 51.74 (Dec. 2025) - 3.301 (Apr. 2015) )
=
7.891
/
48.439
=
16.29%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medclair AB (NGM:MCLR) has a 10-Year ROIIC % of 16.29 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #182 out of 695 companies in the Medical Devices & Instruments industry, placing it in the top 26.2%.
Is Medclair AB's 10-Year ROIIC % too high?
Medclair AB's current 10-Year ROIIC % is 16.29. The Medical Devices & Instruments industry median 10-Year ROIIC % is 2.31. Medclair AB's value of 16.29 is 605.2% above this industry median. Based on the distribution chart, Medclair AB ranks #182 out of 695 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medclair AB has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's 10-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #182 out of 695 companies for 10-Year ROIIC %. This puts Medclair AB in the upper half of its industry. The industry median 10-Year ROIIC % is 2.31. Medclair AB's value of 16.29 is 605.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.31, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current 10-Year ROIIC % of 16.29 is 605.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current 10-Year ROIIC % is 16.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current 10-Year ROIIC % is 16.29 and 605.2% above the Medical Devices & Instruments industry median of 2.31. Medclair AB's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current 10-Year ROIIC % is 16.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
10-Year ROIIC %: 16.29
GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
Industry Position: 605.2% above the Medical Devices & Instruments median (#182 of 695)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
70GF Score
Get the complete analysis for NGM:MCLR
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
